Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects...
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments.
Charter house 66-68 Hills Road Cambridge
Post Code: CB2 1LA
Country: United Kingdom
Membership Type: Corporate 51+